Latest From Genmab AS
Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.
Last year, a total of 67 biopharma and medtech companies completed initial public offerings (IPOs), raising for $8.55bn between them.
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.
German TCR developer in partnerships with GSK and BMS will go public and receive $252m at closing in a reverse merger-type transaction with Arya.
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Genmab AS
- Senior Management
Jan van de Winkel, PhD, Pres. & CEO
David A Eatwell, EVP, CFO
Judith Klimovsky, MD, EVP, Chief Dev. Officer
- Contact Info
Phone: (45) 7020 2728
Kalvebod Brygge 43
Copenhagen, 1560 V